title: Efficacy of procainamide on ventricular tachycardia: relation to prolongation of refractoriness and slowing of conduction.
abstract: The effect of procainamide on intraventricular conduction and refractoriness, and the prevention of induction of ventricular tachycardia (VT) were studied in 29 patients who had remote myocardial infarction and inducible sustained monomorphic VT. AFter intravenous administration of 15 mg/kg procainamide, induction of VT was suppressed in seven (24%) patients (responders), while in 22 (76%) VT was still inducible (nonresponders). The percent change in paced QRS duration at a cycle length (CL) of 400 msec produced by procainamide was significantly less in responders than in nonresponders: 29.8 +/- 3.9% versus 38.9 +/- 10.8% (p = 0.0020). The percent change in the right ventricular effective refractory period (ERP) at CLs of 600 and 400 msec was significantly greater in responders than in nonresponders: 14.6 +/- 6.9% versus 7.9 +/- 7.3% (p = 0.0414) for ERP at a CL of 600 msec and 15.1 +/- 7.0% versus 8.0 +/- 7.4% (p = 0.0386) for ERP at a CL of 400 msec. Stepwise discriminant analysis showed that greater percent increase in ERP at a CL of 400 msec and lesser percent increase in paced QRS duration at a CL of 400 msec were significantly independent markers for the responders. These findings suggest that lesser slowing of conduction and greater prolongation of refractoriness by procainamide tend to abolish reentry within the reentrant circuit. Greater slowing of conduction and lesser prolongation of refractoriness tend to stabilize a reentrant circuit, and promote the continued induction of VT.
authors: Electrophysiology Laboratory, Miami Heart Institute, FL.
authors: T
authors: T
authors: Furukawa
authors: J J
authors: JJ
authors: Rozanski
authors: K
authors: K
authors: Moroe
authors: A J
authors: AJ
authors: Gosselin
authors: J W
authors: JW
authors: Lister
mesh_terms: D004562:Electrocardiography; D006801:Humans; D008991:Monitoring, Physiologic; D009431:Neural Conduction / Q000187:drug effects*; D011342:Procainamide / Q000097:blood / Q000627:therapeutic use*; D012032:Refractory Period, Electrophysiological / Q000187:drug effects; D013318:Stroke Volume / Q000187:drug effects; D013610:Tachycardia / Q000188:drug therapy*
chemical_list: D011342:Procainamide